Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 6
2021 14
2022 19
2023 22
2024 13
2025 11
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 32795346

86 results

Results by year

Filters applied: . Clear all
Page 1
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. O'Brien NA, et al. Breast Cancer Res. 2020 Aug 14;22(1):89. doi: 10.1186/s13058-020-01320-8. Breast Cancer Res. 2020. PMID: 32795346 Free PMC article.
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
Kong T, Mabry A, Highkin M, Wang AZ, Hoog J, Guo Z, Gonzales-Gonzales A, Thomas S, Song Y, Gao F, Opyrchal M, Peterson L, Ademuyiwa F, Margenthaler J, Aft R, Glover-Collins K, Nehring L, Tao Y, Sanati S, Hagemann IS, Boulos F, Holt M, Ding L, Zhu W, Oh ST, Wang J, Witkiewicz AK, Knudsen ES, Bose R, Weber JD, Goetz M, Northfelt D, Luo J, Ma CX. Kong T, et al. Nat Commun. 2026 Jan 27;17(1):949. doi: 10.1038/s41467-026-68570-6. Nat Commun. 2026. PMID: 41593097 Free PMC article. Clinical Trial.
The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma.
Yang Q, Wang Y, Corchete Sanchez LA, Mathavarajah S, Qin Q, Wei Y, Alpert E, Whelton L, Sharma P, Strom S, Oultache I, Iafrate AJ, Pinello L, Rheinbay E, Yan C, Langenau DM. Yang Q, et al. Nat Commun. 2025 Dec 10;17(1):65. doi: 10.1038/s41467-025-66632-9. Nat Commun. 2025. PMID: 41372143 Free PMC article.
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.
Alexandrou S, Lee CS, Fernandez KJ, Wiharja CE, Eshraghi L, Reeves J, Reed DA, Portman N, Phan Z, Milioli HH, Nikolic I, Cadell AL, Croucher DR, Simpson KJ, Lim E, Hickey TE, Millar EKA, Alves CL, Ditzel HJ, Caldon CE. Alexandrou S, et al. J Exp Clin Cancer Res. 2025 Aug 19;44(1):244. doi: 10.1186/s13046-025-03466-9. J Exp Clin Cancer Res. 2025. PMID: 40826108 Free PMC article.
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Wesolowski R, Rugo HS, Specht JM, Han HS, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM. Wesolowski R, et al. Clin Cancer Res. 2025 Oct 1;31(19):4040-4048. doi: 10.1158/1078-0432.CCR-25-0992. Clin Cancer Res. 2025. PMID: 40711480 Free PMC article. Clinical Trial.
Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells.
Tarrado-Castellarnau M, Foguet C, Tarragó-Celada J, Palobart M, Hernández-Carro C, Perarnau J, Zodda E, Polat IH, Marin S, Suarez-Bonnet A, Lozano JJ, Yuneva M, Thomson TM, Cascante M. Tarrado-Castellarnau M, et al. Oncogene. 2025 Sep;44(36):3386-3406. doi: 10.1038/s41388-025-03495-w. Epub 2025 Jul 22. Oncogene. 2025. PMID: 40696167 Free PMC article.
86 results